ISIS PHARMACEUTICALS INC's ticker is ISIS and the CUSIP is 464330109. A total of 4 filers reported holding ISIS PHARMACEUTICALS INC in Q4 2012. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $353,000 | -30.5% | 8,742 | -1.1% | 0.01% | -28.6% |
| Q2 2015 | $508,000 | -8.8% | 8,835 | +1.1% | 0.01% | -12.5% |
| Q1 2015 | $557,000 | +1195.3% | 8,742 | +694.7% | 0.01% | +700.0% |
| Q3 2014 | $43,000 | -99.1% | 1,100 | -99.2% | 0.00% | -99.3% |
| Q2 2014 | $4,861,000 | +44.2% | 141,100 | +80.9% | 0.14% | +37.5% |
| Q1 2014 | $3,371,000 | -10.9% | 78,000 | -17.9% | 0.10% | -16.1% |
| Q4 2013 | $3,785,000 | +34.4% | 95,000 | +26.7% | 0.12% | +27.8% |
| Q3 2013 | $2,816,000 | +249.4% | 75,000 | +150.0% | 0.10% | +246.4% |
| Q2 2013 | $806,000 | +58.7% | 30,000 | 0.0% | 0.03% | +55.6% |
| Q1 2013 | $508,000 | -66.5% | 30,000 | -79.3% | 0.02% | -70.0% |
| Q4 2012 | $1,517,000 | +191.2% | 145,000 | +291.9% | 0.06% | +185.7% |
| Q3 2012 | $521,000 | +8.5% | 37,000 | -7.5% | 0.02% | 0.0% |
| Q2 2012 | $480,000 | -42.4% | 40,000 | -57.9% | 0.02% | -44.7% |
| Q1 2012 | $833,000 | +168.7% | 95,000 | +120.9% | 0.04% | +171.4% |
| Q4 2011 | $310,000 | – | 43,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BB BIOTECH AG | 5,729,426 | $364,793,000 | 10.87% |
| DOWLING & YAHNKE LLC | 676,323 | $43,061,000 | 5.38% |
| WILLIAM HARRIS INVESTORS INC | 229,887 | $14,638,000 | 3.84% |
| Opus Point Partners Management, LLC | 60,912 | $3,878,000 | 3.25% |
| Nepsis Inc. | 64,580 | $4,112,000 | 2.48% |
| Private Capital Advisors, Inc. | 106,320 | $6,769,000 | 2.46% |
| PINNACLE ASSOCIATES LTD | 1,889,017 | $120,274,000 | 2.24% |
| MESSNER & SMITH THEME VALUE INVESTMENT MANAGEMENT LTD /CA/ | 20,947 | $1,333,000 | 1.90% |
| Apex Capital Management | 928,654 | $59,127,000 | 1.39% |
| Bellevue Asset Management AG | 147,000 | $9,359,000 | 1.31% |